Background. Gastrointestinal leak (GIL) after cytoreductive surgery with heated intraperitoneal chemotherapy (CRS/HIPEC) is associated with significant morbidity and mortality. This study aimed to identify GIL prognostic factors and its impact on overall survival. Methods. A retrospective analysis of a prospectively maintained database comprising 1270 CRS/HIPEC procedures was performed. Type of GIL, functional and resection status, morbidity, mortality, and survival were reviewed. Results. Gastrointestinal leaks were identified in 8.7% (110/1270) of CRS/HIPEC procedures, including 53 anastomotic leaks (4.2%), 53 hollow viscus perforations (4.2%), and four leaks at unknown sites. The multivariate predictors of leak were Eastern Cooperative Oncology Group (ECOG) functional status (ECOG 1 vs. 0: odds ratio [OR] 2.12, p = 0.009; ECOG 2 vs. 0: OR 2.90, p = 0.004), and number of anastomoses (OR 5.34; p \ 0.0001). The in-hospital mortality rate for the GIL cohort was 21.8% (24/110), with a 72% (80/110) reoperation rate. The leak cohort had a higher major morbidity rate (88.3 vs. 23.3%; p \ 0.0001), a longer hospital stay (39.0 vs. 9.9 days; p \ 0.0001), and a longer intensive care unit (ICU) stay (7.7 vs. 1.7 days; p = 0.0003). After surgical mortality was excluded, the overall survival periods for the leak and no-leak patients with complete cytoreduction were respectively 1.5 and 4.98 years (p = 0.0001). Clinically significant decreases in survival were observed for all primary malignancies. Conclusions. Gastrointestinal leak after CRS/HIPEC is a source of significant mortality, with a decrease in overall survival even after complete CRS. Preoperative functional status and number of anastomoses are predictors of leak for CRS/HIPEC patients.
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Cytoreductive surgery with heated intraperitoneal chemotherapy (CRS/HIPEC) has emerged as the treatment method of choice for epithelial malignancies with limited intraperitoneal spread. In experienced peritoneal surface disease (PSD) centers, the operation currently is performed with morbidity and mortality directly comparable with the morbidity and mortality reported for surgical oncology procedures of similar extent. 1 The outcome after CRS/HIPEC depends on type of primary malignancy, volume of peritoneal disease, completeness of cytoreduction, and functional status of the patient. 2, 3 However, it is unknown whether chemoperfusion contributes to the severity of common surgical complications, such as gastrointestinal leak (GIL). The impact of GIL on overall survival of PSD patients also is not well defined.
The primary aims of this study were to identify predictors of gastrointestinal leak in CRS/HIPEC patients and its impact on surgical outcomes and to determine the impact of GIL on overall survival of patients who have achieved a complete CRS.
METHODS
A retrospective analysis of a prospectively maintained database comprising 1270 CRS/HIPEC procedures from 1991 to 2015 was performed. The data abstracted included age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, type of primary malignancy, pre-HIPEC chemotherapy, intraperitoneal chemotherapy agent, comorbidities, preoperative albumin, R (completeness of resection) status, total number of organs resected, Peritoneal Cancer Index (PCI) score, 4 estimated blood loss (EBL), and prior Surgical Score (PSS). 5 Data specific to the occurrence of a leak were obtained through chart review and included imaging methods, operative reports, IR drain placement, diversion, timing of the leak, number of anastomoses, and performance of handsewn or stapled anastomosis.
Gastrointestinal leak (GIL) was defined as a leak from the upper or lower gastrointestinal tract and was further subdivided into anastomotic leaks and perforations. Anastomotic leak was defined as a leak from a connection site between two portions of the gastrointestinal tract. Perforation was defined as a leak from sites away from an anastomosis as a result of tumor implant resection in the form of wedge resection, cauterization, or tangential excision. Cases with bile, ureteral, bladder, or pancreatic leaks were excluded from this analysis.
The CRS/HIPEC procedure was performed with the closed technique as previously described by our group. 6 The R0 and R1 resections were analyzed together as complete cytoreductions, whereas CRS with residual macroscopic disease was characterized as R2. Morbidity and mortality were graded on the basis of the ClavienDindo classification. 7 Institutional review board approval was obtained. Descriptive statistics including frequencies and percentages for categorical data, means, and standard deviations for continuous outcomes were calculated for all the study variables. The Kaplan-Meier method was used to estimate survival and standard errors, and the multivariate Cox model was performed for the patient who leaked. Survival of the overall population was investigated, and separate investigations were performed to obtain the survival data for the different primary malignancies. Statistical analyses were performed using SPSS 19 (SPSS, Inc., Chicago, IL, USA) and SAS 9.2 (SAS Institute) software.
RESULTS

Cohort Characteristics
During the study period, 8.7% (110/1270) of cases with GIL were identified. These cases included 53 anastomotic leaks (4.2%), 53 hollow viscus perforations (4.2%), and four leaks from a site not specified in the records. Patients with GIL were more often males (p = 0.01) with poorer ECOG performance status (p \ 0.0001), incomplete cytoreduction (p = 0.0002), and a colorectal resection (p \ 0.0001). The groups were similar in terms of the primary sites and agent of chemoperfusion. Appendiceal tumors were the most prevalent, with 504 identified as low grade (39.7%) and 137 identified as high grade (10.8%). ''Other'' included a heterogeneous group such as small bowel tumors; sarcomas; pancreatic, gallbladder, urachal, adrenal, liver tumors, gynecologic and unknown primary malignancies (Table 1) .
Anastomoses
The mean number of anastomoses in the leak group was 1.14 (125 anastomoses in total), with 52 patients (47.3%) having one, 24 patients (21.8%) having two, 7 patients (6.4%) having three, 1 patient (0.9%) having four, and 26 patients (23.6%) having no anastomoses. These patients included 54 (49.1%) with stapled anastomoses, 17 (15.5%) with hand-sewn anastomoses, 13 (11.8%) with a combination of stapled and hand-sewn anastomoses, and 26 (23.6%) with no anastomoses. The anastomoses included 40 small bowel-to-colon/rectum anastomoses (36.4%), 14 small bowel-to-small bowel anastomoses (12.7%), 5 colocolonic anastomoses (4.5%), and 22 combinations of the aforementioned anastomoses (20%).
A gastric leak occurred in 21 patients (19.1%). Of these, 3 patients (14.3%) had a Billroth I reconstruction, 3 patients (14.3%) had a Billroth II reconstruction, 3 patients (14.3%) had an esophagojejunal anastomosis, 3 patients (14.3%) had a gastrojejunal anastomosis, 1 patient (4.8%) had a stapled partial gastrectomy, 1 patient (4.8%) had a gastrostomy, and 7 patients (33.3%) had no formal gastric resection. The type of anastomosis was not found to be statistically significant in the univariate analysis.
When we dichotomized the institutional experience between the first 15 years and the last 10 years, the leak rate was found to be similar (respectively, 9.6% [41/426] and 8.2% [69/844]; p = 0.40).
Timing and Management of Leak
The median time for diagnosis of a leak was 10 days (interquartile range [IQR], 8 days). Nonsurgical management of a leak with imaging-guided drains was attempted in 31 cases (28.2%). This was successful in avoiding operative therapy for the leak in 19 (62.3%) of these cases. However, 12 (38.7%) of these 31 cases had to return to the operating room for definitive surgical management.
Surgical management of a leak was required in 80 (72.7%) of cases, with 27 patients (24.5%) requiring diverting stomas. Another 11 patients (10%) were medically managed with bowel rest and total parenteral nutrition (TPN) only.
Predictors of Leak
Univariate analysis identified male sex (p = 0.01), EGOG functional status (p \ 0.001), extent of cytoreduction as captured by the number of resected organs (p \ 0.001), number of anastomoses (p \ 0.001), preoperative albumin level (p = 0.03), and estimated blood loss (EBL) (p \ 0.001) to be predictors of a leak. A multivariable logistic regression analysis was performed to identify independent predictors of GIL, including the statistically significant variables from the univariate analysis. The factors that remained significant were ECOG status of 1 versus 0 (OR 2.12; p = 0.009), ECOG status of 2 versus 0 (OR 2.90; p = 0.004), and number of anastomoses (OR 5.34; p \ 0.001) ( Table 2) .
Surgical Outcomes
In the leak cohort, higher major morbidity (grades 3 and 4) (88.3 vs. 23.3%; p \ 0.0001), longer hospital stay (39.0 vs. 9.9 days; p \ 0.0001), and longer intensive care unit (ICU) stay (7.7 vs. 1.70 days; p = 0.0003) were found. The observed mortality rate in the leak cohort was 21.8% (24/110).
A multivariable Cox model of analysis was performed to identify predictors of mortality after a gastrointestinal leak. Gastric primary malignancies (OR 10.21; p = 0.008) and ECOG status of 2 or higher (ECOG 2: OR 3.40; p = 0.0309; ECOG C 3: OR 36.29; p \ 0.0001) were shown to be independent predictors of mortality for the leak group only. Sex (p = 0.92), colon primary malignancy (p = 0. prior Surgical Score (1: p = 0.32; 2: p = 0.47; 3: p = 0.37) were not predictive of mortality after a leak ( Table 3) .
Impact of Gastrointestinal Leak on Survival
In a multivariable Cox proportional hazards regression model, the factors found to be associated with decreased survival after a gastrointestinal leak were pre-HIPEC systemic chemotherapy (hazard ratio [HR] 1.80; p \ 0.0001), ECOG functional status higher than 0 (1: HR 1.28, p = 0.009; 2: HR 1.86, p \ 0.0001), and R2 status of resection (HR 2.62; p \ 0.0001), whereas gastric cancer exhibited the worst survival among all primary malignancies after a leak (HR 4.84; p \ 0.0001). Lower preoperative BMI (HR 0.99; p = 0.003) and prior surgical score of 1 (HR 0.74; p = 0.01) were associated with improved survival after a leak (Table 4) .
After surgical mortality was excluded, the overall survival periods for all the leak and no-leak patients were respectively 1.5 and 4.98 years (p = 0.0001). The patients with complete R0/R1 macroscopic CRS who experienced a leak after CRS/HIPEC, regardless of primary malignancy, showed a decreased median overall survival period of 1.63 years compared with 3.12 years in the no-leak group (p = 0.0007) (Fig. 1) . When survival was studied on the basis of the same primary malignancy and complete R0/R1 macroscopic cytoreduction, after exclusion of surgical mortality, all primary malignancies exhibited clinically worse overall survival after a leak, including appendiceal 
DISCUSSION
Resection of limited peritoneal disease has taken on increasing importance in light of impressive data for CRS/ HIPEC. However, there are lingering concerns regarding the morbidity attendant to the procedure, and gastrointestinal leaks are a feared complication. Gastrointestinal leak after CRS/HIPEC often results in loss of functional status, reduces the ability to mount an immune response, and can delay systemic chemotherapy, with a potentially detrimental effect on survival.
The primary aim of this study was to identify predictors of gastrointestinal leak in CRS/HIPEC patients and its impact on surgical outcomes. The incidence of gastrointestinal leak in the studied cohort was 8.7%, with reported rates in the literature ranging widely between 5 and 34%. [8] [9] [10] [11] The median time for manifestation of a leak was 10 days, considerably longer than the 5 days described for non-HIPEC colorectal procedures. 12 This may have been related to an adverse effect on anastomotic healing from heated intraperitoneal chemotherapy or possibly a late chemotherapy effect on cytoreduced bowel implants. Therefore, given the late presentation of a post-HIPEC gastrointestinal leak, a high index of suspicion needs to be maintained well into the postoperative period to achieve early identification and initiation of treatment.
Predictors of leak in this analysis were found to be the functional status of the patient and the number of anastomoses. 8, 13 Therefore, during cytoreduction, it may be more advantageous to sacrifice additional short lengths of bowel than to risk more than one anastomoses. We were surprised to find that in this analysis, the PCI score was not a predictor of GIL, unlike previous reports in the literature.
14 Although the number of anastomoses was predictive of a leak, 50% of the leak events in the studied cohort were not due to an anastomosis, but rather to late perforations. Therefore, patients with scattered bowel involvement who require resection of multiple bowel implants to achieve a complete CRS are equally prone to the development of a leak even without anastomosis. This should be taken into consideration and specifically looked for during any reexploration of the patient. Isolated resection of small bowel lesions should not be attempted unless a complete CRS is feasible.
Gastrointestinal leak after HIPEC is associated with a 22% mortality rate, similar to the 20% mortality rate described after leak in colorectal procedures not followed by chemoperfusion. 15 In our study, gastric resection was associated with increased mortality, as previously reported by Bartlett et al. 16 We currently perform CRS/HIPEC for Gastrointestinal leak was significant for decreased overall survival only in the univariate analysis (p = 0.0008) and not in the multivariate analysis (p = 0.3). This possibly may have been due to inclusion of different primary malignancies with markedly different biologic behaviors. More specifically, the majority were low-grade appendiceal primary tumors. Patients with these tumors demonstrate a much less aggressive biologic behavior that often allows for the effects of a leak on prognosis to be ameliorated. Therefore, the impact of gastrointestinal leak on overall survival after CRS/HIPEC was evaluated for patients with the same primary tumor who achieved a complete CRS, after exclusion of surgical mortality. Specifically, all completely cytoreduced primary tumors studied showed nearly a 50% reduction in survival compared with complete CRS patients who had no leak.
Although the current study analyzed a large cohort of patients, it was not free of the inherent limitations of a single-institution retrospective review incorporating data collected during 25 years. Selection bias has played a role in the reported outcomes due to evolution of our selection criteria as a result of accumulated institutional experience. In addition, despite the volume of available data, subgroup analysis suffered from low power. Furthermore, most of the patients with poor performance status underwent surgery early in the experience, and we no longer offer CRS/ HIPEC to patients with an ECOG performance status of three or higher. Patients with an ECOG of two also should be selected cautiously on a case-by-case basis, depending on their comorbidities as well as their tumor burden and type of primary.
Determining when to perform CRS/HIPEC for patients with peritoneal dissemination requires a complex multidisciplinary approach that considers the tolerability and efficacy of systemic chemotherapy. To minimize the risk of GIL, any preoperative chemotherapy should be delivered to decrease the PCI score and optimize the likelihood of a complete cytoreduction. However, it should not be administered to the detriment of the patient's performance status because the ECOG status is strongly linked to the risk of major morbidity and GIL. The value of open and regular communication between medical and surgical oncologists is clear in this regard. We typically suggest no more than six cycles of first-line therapy before CRS/ HIPEC if the disease appears to be amenable to complete cytoreduction. It is worth noting that preoperative chemotherapy was associated with decreased survival, but likely represents a surrogate for worse tumor biology.
In conclusion, gastrointestinal leak after CRS/HIPEC is associated with significant mortality, morbidity, prolonged hospital stay, and use of resources. Survival for patients who have experienced a leak after CRS/HIPEC is inferior to that for their non-leak counterparts even when complete macroscopic cytoreduction has been achieved. 
